Ayalew Tefferi

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
  2. ncbi request reprint Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 108:1158-64. 2006
  3. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
  4. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
  5. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
  6. ncbi request reprint Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
  7. ncbi request reprint Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:197-200. 2008
  8. doi request reprint Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
  9. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
  10. ncbi request reprint JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    Alexandra P Wolanskyj
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 131:208-13. 2005

Detail Information

Publications125 found, 100 shown here

  1. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  2. ncbi request reprint Lenalidomide therapy in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 108:1158-64. 2006
    ..We conclude that lenalidomide engenders an intriguing treatment activity in a subset of patients with MMM that includes an unprecedented effect on peripheral blood and bone marrow abnormalities...
  3. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
    ..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
  4. ncbi request reprint The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, and Department of Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Cancer 106:631-5. 2006
    ..Several studies have recently reported on the occurrence of a JAK2(V617F) mutation in myeloid cells from the majority of patients with polycythemia vera (PV). The clinical relevance of this novel observation currently is under study...
  5. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
    ....
  6. ncbi request reprint Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:166-71. 2005
    ..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP...
  7. ncbi request reprint Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:197-200. 2008
    ..02), but not JAK2V617F allele burden, thrombosis, hemorrhage, leukemic/fibrotic transformation, or survival. We conclude that cytogenetic anomalies occur infrequently at PV diagnosis and do not confer an adverse outcome...
  8. doi request reprint Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
    ..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
  9. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
    ..The current study was designed to provide additional data in this regard...
  10. ncbi request reprint JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance
    Alexandra P Wolanskyj
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 131:208-13. 2005
    ..Therefore, although the presence of JAK2(V617F) in ET appears to promote a PV phenotype, it might not carry treatment-relevant information...
  11. doi request reprint Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations
    Stephanie R Fink
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 33:843-6. 2009
    ..Our results revealed this new FISH assay accurately detects these abnormalities and will be a useful clinical test for patients with myeloid neoplasms and eosinophilia...
  12. ncbi request reprint Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stem Cells 25:2358-62. 2007
    ..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
  13. doi request reprint Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 88:201-6. 2013
    ..We conclude that SRSF2 is the most frequently mutated spliceosome gene in CMML but neither it nor SF3B1 or U2AF35 mutations are prognostically relevant...
  14. doi request reprint DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    Naseema Gangat
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:392-7. 2011
    ..The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status...
  15. ncbi request reprint A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  16. ncbi request reprint Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:683-7. 2006
    ..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
  17. ncbi request reprint Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
    Jaya Kittur
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2279-84. 2007
    ..A possible association with thrombotic complication has also been considered...
  18. doi request reprint Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 87:285-93. 2012
    ..Other disease features include leukocytosis, splenomegaly, thrombohemorrhagic complications, vasomotor disturbances, pruritus, and a small risk of disease progression into acute myeloid leukemia or myelofibrosis...
  19. doi request reprint The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
    Shireen Sirhan
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:363-5. 2008
    ..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
  20. doi request reprint Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Am J Hematol 85:238-42. 2010
    ..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
  21. ncbi request reprint Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and
    Ruben A Mesa
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:737-40. 2007
    ....
  22. doi request reprint Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Res 32:1927-30. 2008
    ..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology...
  23. ncbi request reprint MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    Animesh D Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 108:3472-6. 2006
    ..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease...
  24. ncbi request reprint Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:421-30. 2003
    ..To assess the activity of von Willebrand factor-cleaving protease (vWF-CP) in patients with thrombotic thrombocytopenic purpura (TTP) complicating bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT)...
  25. ncbi request reprint The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates
    Ayalew Tefferi
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 131:320-8. 2005
    ....
  26. doi request reprint Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    Kebede Hussein
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 82:255-9. 2009
    ..The presence of 0, 1, 2, and > or =3 adverse factors defines low, intermediate-1, intermediate-2, and high risk disease, respectively. We examined the additional prognostic relevance of karyotype...
  27. ncbi request reprint JAK2 in myeloproliferative disorders is not just another kinase
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cell Cycle 4:1053-6. 2005
    ..Taken together, these observations suggest that JAK2(V617F) is an acquired myeloid lineage-specific mutation that engenders a pathogenetic relevance for the PV phenotype in MPD...
  28. doi request reprint SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:4168-71. 2012
    ..01; HR = 1.9; 95% CI, 1.1-3.0) and IDH mutations (P < .01; HR = 2.3; 95% CI, 1.4-3.8). In conclusion, SRSF2 mutations are relatively common in PMF, cluster with IDH mutations, and are independently predictive of poor outcome...
  29. doi request reprint Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
    Rakhee Vaidya
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 87:1003-5. 2012
    ..This study provides preliminary observations that warrant a larger scale study and suggests the value of plasma cytokines as prognostic biomarkers in PV. Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc...
  30. doi request reprint Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1087-94. 2012
    ..Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest...
  31. doi request reprint SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:569-72. 2012
    ..In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations...
  32. doi request reprint Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1356-63. 2011
    ..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
  33. ncbi request reprint Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
    Naseema Gangat
    Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 138:354-8. 2007
    ..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
  34. doi request reprint 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:386-90. 2008
    ....
  35. ncbi request reprint Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 32:407-11. 2008
    ..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone...
  36. doi request reprint JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:457-9. 2008
    ..Our study also suggests that the natural history of a JAK2V617F-positive "occult" MPN might be different from that of a typical MPN...
  37. ncbi request reprint Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1739-43. 2006
    ..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
  38. ncbi request reprint Myelofibrosis with myeloid metaplasia: new developments in pathogenesis and treatment
    David Dingli
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Intern Med 43:540-7. 2004
    ..Among the novel agents tested, thalidomide seems the most promising although newer agents are on the horizon...
  39. pmc Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years
    Rakhee Vaidya
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1114-9. 2009
    ..002), not in those with low-risk disease (P=.42). These observations are encouraging and suggest a salutary effect from modern therapeutic approaches in PMF...
  40. ncbi request reprint Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 104:1881-7. 2004
    ..Using this system, 49%, 38%, and 13% of patients were in stage I, stage II, and stage III, respectively. Determining levels of circulating biomarkers may be the most powerful tool for staging patients with AL undergoing PBSCT...
  41. pmc Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:158-64. 2010
    ..In the current review, we provide a simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia and discuss current therapy, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab)...
  42. doi request reprint Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patients
    Mrinal M Patnaik
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:393-8. 2011
    ....
  43. doi request reprint Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:5674-7. 2012
    ..Neither univariate nor multivariable analysis showed significant effect for RS% on overall or leukemia-free survival, suggesting the limited prognostic value of quantifying BM RS in MDS...
  44. pmc One thousand patients with primary myelofibrosis: the mayo clinic experience
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:25-33. 2012
    ..To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results...
  45. ncbi request reprint Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?
    David P Steensma
    Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:235-42. 2003
    ..Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings...
  46. ncbi request reprint How to interpret and pursue an abnormal complete blood cell count in adults
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:923-36. 2005
    ..The objective is to help the nonhematologist recognize when a subspecialty consultation is reasonable and when it may be circumvented, thus allowing a cost-effective and intellectually rewarding practice...
  47. doi request reprint Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:14-7. 2010
    ..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
  48. ncbi request reprint The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma
    Yinlee Yoong
    Division of Hematology, Department of Internal Medecine, Mayo Clinic, Rochester, MN 55909, USA
    Leuk Lymphoma 46:1287-94. 2005
    ..0001). Multivariate analysis demonstrated K-ALC recovery post-ASCT to be an independent prognostic indicator for OS and PFS. These data support our hypothesis that the K-ALC post-ASCT is associated with clinical outcome in NHL...
  49. ncbi request reprint Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:623-30. 2006
    ..The current study describes the natural history of AMM in transplant-eligible patients and proposes a new prognostic scoring system that favorably compares with other established models...
  50. ncbi request reprint Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia
    Brijesh Arora
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Haematologica 89:1454-8. 2004
    ..This issue is further examined in the current prospective study and clinico-pathological correlates sought...
  51. ncbi request reprint Risk-based management of myelodysplastic syndrome
    David P Steensma
    Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 21:43-54; discussion 57-8, 62. 2007
    ..While many questions remain about the optimal use of newer agents, the long-standing perception of MDS as a syndrome where therapeutic nihilism is the only realistic approach is slowly beginning to change...
  52. ncbi request reprint Eosinophilia: secondary, clonal and idiopathic
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:468-92. 2006
    ..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
  53. ncbi request reprint Platelet-rich plasma serotonin levels in chronic myeloproliferative disorders: evaluation of diagnostic use and comparison with the neutrophil PRV-1 assay
    Cody A Koch
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 127:34-9. 2004
    ..86% test accuracy). The current study suggests that PRP serotonin concentration might be considered as one of the several biological markers that complement each other for the diagnosis of PV...
  54. ncbi request reprint Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia
    Yinlee Yoong
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:124-7. 2005
    ..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions...
  55. doi request reprint Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:3769-72. 2009
    ....
  56. ncbi request reprint Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis
    Luis F Porrata
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 11:1210-8. 2005
    ..The relationship of ALC-15 with clinical outcomes in primary systemic amyloidosis is unknown...
  57. ncbi request reprint Primer on medical genomics. Part III: Microarray experiments and data analysis
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:927-40. 2002
    ..The current review should serve as an introduction to the subject for clinician investigators, physicians and medical scientists in training, practicing clinicians, and other students of medicine...
  58. doi request reprint Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 88:237-43. 2012
    ..Therapy-related APL is sensitive to standard therapy with no cases of resistance or relapse seen. The inferior OS of the t-APL was due to induction mortality, possibly reflecting prior therapy...
  59. doi request reprint Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications
    Fareeda Taher Nazer Hussain
    Mayo Medical School, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 87:684-6. 2012
    ..57 and 0.81, respectively). The current study does not prognostically distinguish monosomy 7 from 7q- or der(1;7), in MDS...
  60. doi request reprint Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:789-96. 2011
    ..Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor...
  61. doi request reprint Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years
    Pankaj Malhotra
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 49:1724-30. 2008
    ..All surviving patients displayed excellent performance status without ongoing chronic graft versus host disease. We conclude that ASCT is an effective salvage therapy for fludarabine-refractory CLL but late relapses can occur...
  62. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  63. ncbi request reprint Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia
    David P Steensma
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:47-53. 2005
    ..In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations...
  64. doi request reprint Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
    Ken Hong Lim
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 113:5727-36. 2009
    ..The current study validates the prognostic relevance of the WHO subclassification of SM and provides additional information of value in terms of both risk stratification and interpretation of clinical presentation and laboratory results...
  65. ncbi request reprint JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, United States
    Leuk Res 30:1457-60. 2006
    ....
  66. ncbi request reprint CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 102:3093-6. 2003
    ..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
  67. doi request reprint Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
    Naseema Gangat
    Division of Hematology, Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota55905, USA
    Am J Hematol 83:451-3. 2008
    ..30%; P = 0.003). Multivariable analysis revealed that these associations were independent of other risk factors for thrombosis. High JAK2V617F allele burden clustered with pruritus (P = 0.002) but did not affect thrombosis rates...
  68. doi request reprint Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
    Ayalew Tefferi
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 118:4595-8. 2011
    ..2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches...
  69. ncbi request reprint Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:1656-60. 2005
    ..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
  70. doi request reprint Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia
    William J Hogan
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 2:34-42. 2007
    ....
  71. ncbi request reprint Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients
    Brijesh Arora
    Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 128:42-8. 2005
    ..The current prospective study does not support an independent prognostic value for PB CD34 count in MMM...
  72. ncbi request reprint Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients
    Bekele Afessa
    Department of Medicine, Divisions of Pulmonary and Critical Care Medicine and Hematology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 166:1364-8. 2002
    ..This study shows that survival rate of hematopoietic stem cell transplant recipients with diffuse alveolar hemorrhage is better than previously reported, and that early onset and autologous transplant are favorable prognostic indicators...
  73. ncbi request reprint Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia
    Michelle A Elliot
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Eur J Haematol 68:175-9. 2002
    ....
  74. ncbi request reprint Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
    Terra L Reeder
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1981-3. 2003
    ..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution...
  75. doi request reprint Molecular diagnosis of myeloproliferative neoplasms
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Expert Rev Mol Diagn 9:481-92. 2009
    ..In patients with clonal eosinophilic disorders and mast cell disease, the use of molecular diagnostics to identify novel mutations and gene rearrangements, has resulted in superior diagnostic and therapeutic strategies...
  76. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:3391-7. 2003
    ..Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy...
  77. ncbi request reprint Cytogenetic and molecular genetic aspects of essential thrombocythemia
    David P Steensma
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Acta Haematol 108:55-65. 2002
    ..In the future, global analysis of gene expression patterns may help overcome diagnostic dilemmas, refine disease classification, and lead to an improved understanding of the pathogenesis of ET...
  78. ncbi request reprint Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:390-402. 2005
    ..These issues are discussed within the context of clinical practice...
  79. ncbi request reprint Primer on medical genomics part II: Background principles and methods in molecular genetics
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:785-808. 2002
    ....
  80. ncbi request reprint Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1169-75. 2002
    ..To study clinicopathologic correlations and identify prognostically important variables in patients with systemic mast cell disease (SMCD) who have no associated hematologic disorders...
  81. ncbi request reprint Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:739-42. 2003
    ..In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia...
  82. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:S47-52. 2004
    ..These observations make it necessary to re-examine current disease classification and treatment algorithms in eosinophilic disorders...
  83. ncbi request reprint Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 104:1931-9. 2004
    ..Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia...
  84. ncbi request reprint C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders
    Jonathan S C Caudill
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 133:638-41. 2006
    ..All other patients were NPM1-wild type in the region analysed. In conclusion, C-terminal NPM mutations are uncommon in chronic myeloid neoplasia, but if present may represent an evolving leukaemic clone...
  85. ncbi request reprint Clinical features in T-cell vs. natural killer-cell variants of large granular lymphocyte leukemia
    Michelle A Neben
    Division of Hematology and Internal Medicine Division of Hematopathology, Mayo Clinic, Mayo Medical School, Rochester, MN 55905, USA
    Eur J Haematol 71:263-5. 2003
    ....
  86. ncbi request reprint Pharmacotherapy of essential thrombocythemia
    Naseema Gangat
    Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Pharmacother 9:1679-85. 2008
    ..Advanced age and a prior history of thrombosis are the major predictors of thrombotic complications...
  87. ncbi request reprint Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia
    Leonardo N Faoro
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Eur J Haematol 74:117-20. 2005
    ..The purpose of this study is to provide long-term follow-up on the durability of response in the initial cohort and in additional subsequent cases...
  88. ncbi request reprint Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
    Benjamin M F Mow
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55901, USA
    Blood 99:664-71. 2002
    ..Collectively, these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines...
  89. ncbi request reprint Bone marrow angiogenesis in systemic mast cell disease
    Jin Young Baek
    Divisions of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hematother Stem Cell Res 11:139-46. 2002
    ..We conclude that bone marrow angiogenesis characterizes a percentage of patients with SMCD and that the pathogenesis may not necessarily be linked to the mast cells themselves...
  90. pmc Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus
    Y Nancy You
    Department of Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Ann Surg 240:286-92. 2004
    ..To determine the efficacy of splenectomy for treating thrombocytopenia associated with systemic lupus erythematosus (SLE)...
  91. ncbi request reprint Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:883-5. 2003
    ..The clinical implications of this finding are discussed...
  92. ncbi request reprint Agnogenic myeloid metaplasia with pleural extramedullary leukemic transformation
    Hassan F Nadrous
    Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Leuk Lymphoma 45:815-8. 2004
    ..He was hospitalized for neutropenic fever and was diagnosed to have pulmonary aspergillosis. He died of multisystem failure 8 1/2 months after being diagnosed with AMM...
  93. ncbi request reprint Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells
    Joya Chandra
    Division of Oncology Research, Guggenheim 1301, Mayo Clinic, 200 First St, SW, Rochester, MN 55901, USA
    Blood 102:4512-9. 2003
    ....
  94. ncbi request reprint Current management of polycythemia vera
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 43:1-7. 2002
    ..The role of aspirin is being readdressed by an ongoing controlled study. Transformation of PV into either myelofibrosis with myeloid metaplasia or acute leukemia remains a major complication that may not be influenced by current therapy...
  95. ncbi request reprint The prognostic significance of trisomy 8 in patients with acute myeloid leukemia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 43:583-6. 2002
    ..The presence of +8 did not appear to adversely affect the outcome of patients with favorable karyotypes...
  96. ncbi request reprint Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease
    Jin Young Baek
    Division of Hematopathology and Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 26:83-90. 2002
    ..The results confirm the diagnostic value of Kit immunohistochemistry in MCD and suggest a biologically relevant heterogeneity in TGFbeta1R expression among patients with SMCD-HD...
  97. doi request reprint International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis
    Kebede Hussein
    Divisions of Hematology, Hematopathology, Mayo Clinic, Rochester, MN, USA
    Blood 115:496-9. 2010
    ..37; 95% confidence interval, 0.24-0.58) cytogenetic risk categorization (P < .01). The ability to prognostically dissect a specific IPSS category has major therapeutic implications...
  98. ncbi request reprint Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new
    Ayalew Tefferi
    Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Semin Hematol 40:18-21. 2003
    ..Optimal therapy for an individual patient requires a sound understanding of disease risk factors, as well as a full appreciation of the risk to benefit ratio for a specific treatment modality...
  99. ncbi request reprint The rise and fall of red cell mass measurement in polycythemia vera
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Curr Hematol Rep 4:213-7. 2005
    ....
  100. ncbi request reprint Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia
    Andrew P Landstrom
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Leuk Lymphoma 47:2055-61. 2006
    ..0001 for each). Furthermore, we demonstrate that peripheral blood D-FISH can be used as a surrogate for cytogenetic studies in monitoring cytogenetic remission status...
  101. ncbi request reprint Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia
    Brijesh Arora
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 45:2373-86. 2004
    ..In the current review, we summarize the general concepts regarding angiogenesis, assessment of angiogenesis in hematological malignancies and then the current literature on angiogenesis and anti-angiogenic therapy in MMM...